Literature DB >> 27127417

Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs.

Lucy Platt1, Jennifer Reed2, Silvia Minozzi3, Peter Vickerman4, Holly Hagan2, Clare French4, Ashly Jordan2, Louisa Degenhardt5, Vivian Hope6, Sharon Hutchinson7, Lisa Maher8, Norah Palmateer7, Avril Taylor9, Matthew Hickman4.   

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the impact of needle/syringe programmes with and without opiate substitution therapy (OST) on the incidence of HCV infection among people who inject drugs (PWID).To assess the effect of OST alone on the incidence of HCV infection among PWID. RESEARCH QUESTIONS: How effective are needle/syringe programmes (NSP) with and without the use of OST for reducing HCV incidence among PWID?How effective is OST alone for reducing HCV incidence among PWID?How does the effect of NSP and OST vary according to duration of treatment (i.e. for NSPs weekly attendance versus monthly)?How does the effect of NSP vary according to the type of service (fixed site versus mobile; high coverage versus low coverage)?How does the effect of OST vary according to the dosage of OST, type of substitution used and adherence to treatment?

Entities:  

Year:  2016        PMID: 27127417      PMCID: PMC4843520          DOI: 10.1002/14651858.CD012021

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  22 in total

Review 1.  Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment.

Authors:  Enrique R Pouget; Holly Hagan; Don C Des Jarlais
Journal:  Addiction       Date:  2012-04-17       Impact factor: 6.526

2.  Grading quality of evidence and strength of recommendations.

Authors:  David Atkins; Dana Best; Peter A Briss; Martin Eccles; Yngve Falck-Ytter; Signe Flottorp; Gordon H Guyatt; Robin T Harbour; Margaret C Haugh; David Henry; Suzanne Hill; Roman Jaeschke; Gillian Leng; Alessandro Liberati; Nicola Magrini; James Mason; Philippa Middleton; Jacek Mrukowicz; Dianne O'Connell; Andrew D Oxman; Bob Phillips; Holger J Schünemann; Tessa Tan-Torres Edejer; Helena Varonen; Gunn E Vist; John W Williams; Stephanie Zaza
Journal:  BMJ       Date:  2004-06-19

3.  An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations.

Authors:  Holger J Schünemann; Roman Jaeschke; Deborah J Cook; William F Bria; Ali A El-Solh; Armin Ernst; Bonnie F Fahy; Michael K Gould; Kathleen L Horan; Jerry A Krishnan; Constantine A Manthous; Janet R Maurer; Walter T McNicholas; Andrew D Oxman; Gordon Rubenfeld; Gerard M Turino; Gordon Guyatt
Journal:  Am J Respir Crit Care Med       Date:  2006-09-01       Impact factor: 21.405

4.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.

Authors:  Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann
Journal:  BMJ       Date:  2008-04-26

Review 5.  Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews.

Authors:  Norah Palmateer; Jo Kimber; Matthew Hickman; Sharon Hutchinson; Tim Rhodes; David Goldberg
Journal:  Addiction       Date:  2010-03-02       Impact factor: 6.526

Review 6.  A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs.

Authors:  Holly Hagan; Enrique R Pouget; Don C Des Jarlais
Journal:  J Infect Dis       Date:  2011-07-01       Impact factor: 5.226

7.  HIV and risk environment for injecting drug users: the past, present, and future.

Authors:  Steffanie A Strathdee; Timothy B Hallett; Natalia Bobrova; Tim Rhodes; Robert Booth; Reychad Abdool; Catherine A Hankins
Journal:  Lancet       Date:  2010-07-24       Impact factor: 79.321

Review 8.  Methadone at tapered doses for the management of opioid withdrawal.

Authors:  Laura Amato; Marina Davoli; Silvia Minozzi; Eliana Ferroni; Robert Ali; Marica Ferri
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

Review 9.  Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis.

Authors:  Georgie J MacArthur; Silvia Minozzi; Natasha Martin; Peter Vickerman; Sherry Deren; Julie Bruneau; Louisa Degenhardt; Matthew Hickman
Journal:  BMJ       Date:  2012-10-03

10.  Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users.

Authors:  Charlotte Van Den Berg; Colette Smit; Giel Van Brussel; Roel Coutinho; Maria Prins
Journal:  Addiction       Date:  2007-09       Impact factor: 6.526

View more
  23 in total

Review 1.  Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era.

Authors:  O Falade-Nwulia; M S Sulkowski; A Merkow; C Latkin; S H Mehta
Journal:  J Viral Hepat       Date:  2018-03       Impact factor: 3.728

2.  Modeling Combination HCV Prevention among HIV-infected Men Who Have Sex With Men and People Who Inject Drugs.

Authors:  Natasha K Martin; Britt Skaathun; Peter Vickerman; David Stuart
Journal:  AIDS Rev       Date:  2017 Apr - Jun       Impact factor: 2.500

Review 3.  Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.

Authors:  Lucy Platt; Silvia Minozzi; Jennifer Reed; Peter Vickerman; Holly Hagan; Clare French; Ashly Jordan; Louisa Degenhardt; Vivian Hope; Sharon Hutchinson; Lisa Maher; Norah Palmateer; Avril Taylor; Julie Bruneau; Matthew Hickman
Journal:  Cochrane Database Syst Rev       Date:  2017-09-18

4.  Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.

Authors:  Hannah Fraser; Christinah Mukandavire; Natasha K Martin; David Goldberg; Norah Palmateer; Alison Munro; Avril Taylor; Matthew Hickman; Sharon Hutchinson; Peter Vickerman
Journal:  Addiction       Date:  2018-07-10       Impact factor: 6.526

5.  Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic.

Authors:  Hannah Fraser; Jon Zibbell; Thomas Hoerger; Susan Hariri; Claudia Vellozzi; Natasha K Martin; Alex H Kral; Matthew Hickman; John W Ward; Peter Vickerman
Journal:  Addiction       Date:  2017-09-20       Impact factor: 6.526

6.  Hepatitis C Virus Incidence in a Cohort in Medication-Assisted Treatment for Opioid Use Disorder in New York City.

Authors:  Ashly E Jordan; Charles M Cleland; Katarzyna Wyka; Bruce R Schackman; David C Perlman; Denis Nash
Journal:  J Infect Dis       Date:  2020-09-02       Impact factor: 5.226

Review 7.  Understanding and Addressing Hepatitis C Virus Reinfection Among Men Who Have Sex with Men.

Authors:  Thomas C S Martin; Andri Rauch; Luisa Salazar-Vizcaya; Natasha K Martin
Journal:  Infect Dis Clin North Am       Date:  2018-06       Impact factor: 5.982

8.  Usage of low dead space syringes and association with hepatitis C prevalence amongst people who inject drugs in the UK.

Authors:  Adam Trickey; Margaret T May; Vivian Hope; Zoe Ward; Monica Desai; Ellen Heinsbroek; Matthew Hickman; Peter Vickerman
Journal:  Drug Alcohol Depend       Date:  2018-09-15       Impact factor: 4.492

9.  Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users.

Authors:  Marian Major; Alexander Gutfraind; Louis Shekhtman; Qingwen Cui; Alla Kachko; Scott J Cotler; Behzad Hajarizadeh; Rachel Sacks-Davis; Kimberly Page; Basmattee Boodram; Harel Dahari
Journal:  Sci Transl Med       Date:  2018-07-11       Impact factor: 17.956

10.  HIV and the liver.

Authors:  Kenneth E Sherman; Marion G Peters; David L Thomas
Journal:  Top Antivir Med       Date:  2019-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.